MA45831A - Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation - Google Patents

Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Info

Publication number
MA45831A
MA45831A MA045831A MA45831A MA45831A MA 45831 A MA45831 A MA 45831A MA 045831 A MA045831 A MA 045831A MA 45831 A MA45831 A MA 45831A MA 45831 A MA45831 A MA 45831A
Authority
MA
Morocco
Prior art keywords
production
monoclonal antibodies
use processes
bed anti
body monoclonal
Prior art date
Application number
MA045831A
Other languages
English (en)
Other versions
MA45831B1 (fr
Inventor
William John Hall
Min Wang
Original Assignee
Redcoat Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redcoat Solutions Inc filed Critical Redcoat Solutions Inc
Publication of MA45831A publication Critical patent/MA45831A/fr
Publication of MA45831B1 publication Critical patent/MA45831B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B22F1/0545—Dispersions or suspensions of nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0043—Preparation of sols containing elemental metal
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2301/00—Metallic composition of the powder or its coating
    • B22F2301/25—Noble metals, i.e. Ag Au, Ir, Os, Pd, Pt, Rh, Ru
    • B22F2301/255—Silver or gold
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/054—Particle size between 1 and 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/056—Particle size above 100 nm up to 300 nm
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA45831A 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation MA45831B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562244189P 2015-10-21 2015-10-21
PCT/US2016/058300 WO2017070603A1 (fr) 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Publications (2)

Publication Number Publication Date
MA45831A true MA45831A (fr) 2019-06-12
MA45831B1 MA45831B1 (fr) 2023-10-31

Family

ID=58558142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45831A MA45831B1 (fr) 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Country Status (14)

Country Link
US (3) US10768172B2 (fr)
EP (2) EP4273235B1 (fr)
AU (2) AU2016342373B2 (fr)
CA (1) CA3041460A1 (fr)
ES (1) ES2953484T3 (fr)
HR (1) HRP20231035T1 (fr)
HU (1) HUE063822T2 (fr)
MA (1) MA45831B1 (fr)
MD (1) MD3365367T2 (fr)
MX (2) MX2018004986A (fr)
PL (1) PL3365367T3 (fr)
RS (1) RS64530B1 (fr)
SM (1) SMT202300278T1 (fr)
WO (1) WO2017070603A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66220B1 (sr) 2015-10-21 2024-12-31 Redcoat Solutions Inc Uređaj za detekciju krevetnih stenica
CA3041460A1 (fr) * 2015-10-21 2017-04-27 Redcoat Solutions, Inc. Anticorps monoclonaux anti-punaises de lit et leurs procedes de production et d'utilisation
EP4056033B1 (fr) 2017-05-22 2023-09-06 Corteva Agriscience LLC Détection sélective de punaises de lit
EP3883376B1 (fr) 2018-11-21 2024-09-25 Ecolab USA Inc. Détection sélective des punaises des lits

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
AU4562599A (en) 1998-06-12 1999-12-30 New Horizons Diagnostics, Inc. Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles
EP1232392B2 (fr) 1999-10-12 2014-04-02 Oxoid (Ely) Limited Procede de detection de bacteries acido-resistantes du genre helicobacter dans les selles
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7220597B2 (en) 2003-01-30 2007-05-22 Zin Benedict L Assay test device and method of making same
US7214542B2 (en) 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
US7482128B2 (en) * 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
DE602006015330D1 (de) 2005-07-27 2010-08-19 Cytosignet Inc Nachweis und messung einer blutzuführungsaktivität
US7591099B2 (en) 2005-08-30 2009-09-22 Ecolab Inc. Bed bug monitor
AU2013200548B2 (en) 2006-10-23 2015-06-18 Ecolab Usa Inc. Bedbug detection, monitoring and control techniques
AU2007309475B2 (en) 2006-10-23 2012-11-08 Ecolab Usa Inc. Bedbug detection, monitoring and control techniques
US20100273177A1 (en) 2006-12-08 2010-10-28 Piasio Roger N Methods and Devices for Testing Saliva
EP1933145B1 (fr) 2006-12-11 2011-09-28 AraGen Biotechnology Co. Ltd. Détection rapide immunochromatographique par amplification du signal d'or colloïdal
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101688228B (zh) 2007-03-13 2014-12-24 国家犾太健康中心 抗体产生的方法
EP2152416A1 (fr) 2007-04-20 2010-02-17 Quidel Corporation Dispositifs d'analyse avec dessicatif intégré
US20090155921A1 (en) 2007-12-12 2009-06-18 Arbor Vita Corporation Method and apparatus for reading test strips
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
GB0809995D0 (en) 2008-05-31 2008-07-09 Spd Swiss Prec Diagnostics Gmb Assay device
GB0900669D0 (en) 2009-01-16 2009-02-25 Bed Bugs Ltd Pest control
US20100212213A1 (en) 2009-02-25 2010-08-26 Hope Iii Joe Harold Detection device and method for monitoring bed bug infestation
KR20110132352A (ko) 2009-03-13 2011-12-07 에프엠씨 코포레이션 빈대 유인용 조성물
US8577986B2 (en) 2010-04-02 2013-11-05 Microsoft Corporation Mapping RDMA semantics to high speed storage
US20110289824A1 (en) 2010-05-28 2011-12-01 Tai-Teh Wu Compounds, methods, and devices for detecting and/or treating insect infestation
FI20115285A0 (fi) 2011-03-24 2011-03-24 Reagena Ltd Oy Menetelmä pikatestin suorittamiseksi
US9458512B2 (en) 2011-07-05 2016-10-04 Ernest Colaizzi Kit for the detection of bed bugs
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9140693B2 (en) 2011-12-23 2015-09-22 Abbott Point Of Care Inc. Integrated test device for optical detection of microarrays
WO2013130613A1 (fr) 2012-02-29 2013-09-06 Sri International Détection d'ectoparasites
US20130208114A1 (en) 2013-01-25 2013-08-15 Jody Arthur Balsam Digital Bedbug Indicator: A bedbug insect peripheral electronic detection unit device
GB2524307B (en) 2014-03-20 2016-04-20 Rentokil Initial Plc Apparatus
GB2558097B (en) 2014-04-17 2019-03-06 Z Integrated Digital Tech Inc Electronic test device data communication
CN107922467A (zh) 2015-08-31 2018-04-17 爱尔梅德健康集团有限公司 新型蛋白质及检测方法
RS66220B1 (sr) 2015-10-21 2024-12-31 Redcoat Solutions Inc Uređaj za detekciju krevetnih stenica
CA3041460A1 (fr) * 2015-10-21 2017-04-27 Redcoat Solutions, Inc. Anticorps monoclonaux anti-punaises de lit et leurs procedes de production et d'utilisation

Also Published As

Publication number Publication date
AU2016342373B2 (en) 2023-09-21
EP3365367A1 (fr) 2018-08-29
HUE063822T2 (hu) 2024-02-28
AU2016342373A1 (en) 2018-06-07
ES2953484T3 (es) 2023-11-13
HRP20231035T1 (hr) 2023-12-22
EP4273235B1 (fr) 2025-04-09
MX2023009584A (es) 2023-08-23
EP4273235A2 (fr) 2023-11-08
AU2023282327A1 (en) 2024-01-18
US12030933B2 (en) 2024-07-09
MA45831B1 (fr) 2023-10-31
RS64530B1 (sr) 2023-09-29
PL3365367T3 (pl) 2023-10-30
WO2017070603A9 (fr) 2018-05-17
EP4273235A3 (fr) 2024-01-17
EP4273235C0 (fr) 2025-04-09
MD3365367T2 (ro) 2024-02-29
US20250026817A1 (en) 2025-01-23
SMT202300278T1 (it) 2023-09-06
US20170137501A1 (en) 2017-05-18
US10768172B2 (en) 2020-09-08
EP3365367A4 (fr) 2019-06-12
EP3365367B1 (fr) 2023-06-07
US20200363405A1 (en) 2020-11-19
MX2018004986A (es) 2019-01-14
EP3365367C0 (fr) 2023-06-07
WO2017070603A1 (fr) 2017-04-27
CA3041460A1 (fr) 2017-04-27

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
EP3645050A4 (fr) Anticorps multipécifiques et procédés de production et d'utilisation associés
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA47691A (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
EP3307321A4 (fr) Plate-forme d'anticorps multi-spécifiques et procédés associés
MA44054A (fr) Plateforme d'anticorps bispécifique
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation